文献速递贫血与红细胞疾病血栓与止血

抗PD-1或抗PD-L1免疫治疗诱导的血液学免疫相关不良事件:一项描述性观察研究

Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.
PubMed 文献 · Lancet Haematol · 2018-12-04

该描述性观察研究纳入法国三个药物警戒数据库中2014年6月27日至2018年6月29日登记的35例与抗PD-1或抗PD-L1相关的2级及以上血液学免疫相关不良事件患者,中位年龄65岁,最常见为中性粒细胞减少、自身免疫性溶血性贫血和免疫性血小板减少症(各9例[26%]),25例(71%)为4级,2例(6%)死于发热性中性粒细胞减少;REISAMIC前瞻性登记中发生频率为0.5%。

要点

  • 抗PD-1/PD-L1相关血液学irAEs罕见(REISAMIC登记频率0.5%),但25例(71%)达4级,2例(6%)死亡。
  • 最常见类型为中性粒细胞减少、自身免疫性溶血性贫血和免疫性血小板减少症,各占9例(26%)。
  • 35例中21例(60%)血液学irAE缓解。

核心结论

  • 抗PD-1或抗PD-L1抑制剂诱导的血液学irAEs罕见但可能危及生命,最常见的临床表现为中性粒细胞减少、自身免疫性溶血性贫血、免疫性血小板减少症和再生障碍性贫血,有必要开展早期发现和更好管理的研究。

研究设计与样本

  • 描述性观察研究,纳入三个法国药物警戒数据库(REISAMIC前瞻性单中心登记、Gustave Roussy的ImmunoTOX委员会全国转诊数据库、CeReCAI全国自身免疫性血细胞减少数据库)中2014年6月27日至2018年6月29日登记的年龄≥18岁、抗PD-1或抗PD-L1诱导的2级及以上血液学irAE连续患者。
  • 病例由中心委员会审核,不良事件须判定为与抗PD-1或抗PD-L1治疗肯定或很可能相关,严重程度按不良事件通用术语标准(CTCAE)4.03版评估。
  • 主要终点为所有数据库中报告的血液学irAE的临床描述,以及前瞻性REISAMIC登记中报告的频率。

主要发现

  • 共筛查三个数据库948例患者(REISAMIC 745例、ImmunoTOX委员会190例、CeReCAI 13例),最终纳入35例(男21例、女14例)与抗PD-1或抗PD-L1相关的血液学irAE患者。
  • REISAMIC登记中745例接受抗PD-1或抗PD-L1治疗的患者中4例发生血液学irAE,频率为0.5%。
  • 35例患者中位年龄65岁(IQR 51-75),最常见肿瘤类型为黑色素瘤(15例[43%])、非小细胞肺癌(12例[34%])和淋巴瘤(4例[11%]);20例(57%)接受纳武利尤单抗,14例(40%)接受帕博利珠单抗,1例(3%)接受阿替利珠单抗。
  • 35例中最常见血液学irAE类型为中性粒细胞减少、自身免疫性溶血性贫血和免疫性血小板减少症(各9例[26%]),其次为全血细胞减少或再生障碍性贫血(5例[14%])、双系血细胞减少(血小板减少加贫血1例和中性粒细胞减少加贫血1例[6%])及纯红细胞再生障碍(1例[3%])。
  • 严重程度最高分级为2级3例(9%)、3级5例(14%)、4级25例(71%);2例(6%)在抗PD-1相关血液学irAE期间死于发热性中性粒细胞减少;35例中21例(60%)血液学irAE缓解。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anti-programmed cell death 1 (PD-1) and anti-programmed cell death ligand 1 (PD-L1) antibodies are novel immunotherapies for cancer that can induce immune-related adverse events (irAEs). These adverse events can involve all organs, including the haemopoietic system. Thus far, haematological irAEs (haem-irAEs) have not been extensively characterised. This study aims to provide a comprehensive report of the haem-irAEs induced by anti-PD-1 or anti-PD-L1. METHODS: In this descriptive observational study, we included consecutive patients aged at least 18 years with grade 2 or worse haem-irAEs induced by anti-PD-1 or anti-PD-L1 immunotherapy registered in three French pharmacovigilance databases: the Registre des Effets Indésirables Sévères des Anticorps Monoclonaux Immunomodulateurs en Cancérologie (REISAMIC; a prospective registry of patients treated with anti-PD-1 or anti-PD-L1 at a single centre), the ImmunoTOX committee of Gustave Roussy (a national referral database of suspected irAEs in patients treated with immunotherapy), and the registry of the Centre de Référence des Cytopénies Auto-Immunes de l'Adulte (CeReCAI; a national database of autoimmune cytopenias). Cases were reviewed by a central committee; adverse events had to be classed as certainly or probably related to anti-PD-1 or anti-PD-L1 therapy, and their severity was assessed according to the Common Terminology Criteria for Adverse Events (version 4.03). The primary endpoint was clinical description of haem-irAEs, as reported in all databases, and their frequency, as reported in the prospective REISAMIC registry. FINDINGS: We screened 948 patients registered in the three databases from June 27, 2014, to June 29, 2018 (745 from REISAMIC, 190 from the ImmunoTOX committee, and 13 from CeReCAI). 35 patients (21 men and 14 women) with haem-irAEs related to anti-PD-1 or anti-PD-L1 were included in the study. Of 745 patients in the REISAMIC registry treated with anti-PD-1 or anti-PD-L1, four had haem-irAEs, giving a frequency of 0·5%. Median age in the 35 patients was 65 years (IQR 51-75), and the most common tumour types were melanoma (15 [43%] patients), non-small-cell lung cancer (12 [34%] patients), and lymphoma (four [11%] patients). 20 (57%) patients received nivolumab, 14 (40%) received pembrolizumab, and one (3%) received atezolizumab. Among the 35 patients, neutropenia, autoimmune haemolytic anaemia, and immune thrombocytopenia were the most common types of haem-irAE (each in nine patients [26%]), followed by pancytopenia or aplastic anaemia (five patients [14%]), bicytopenia (one patients with thrombocytopenia plus anaemia and one patient with neutropenia plus anaemia [6%]), and pure red cell aplasia (one patient [3%]). The maximum grade of severity was grade 2 in three (9%) patients, grade 3 in five (14%) patients, and grade 4 in 25 (71%) patients; two (6%) patients died from febrile neutropenia during haem-irAE related to anti-PD-1. Haem-irAEs resolved in 21 (60%) of the 35 patients. INTERPRETATION: Haem-irAEs induced by PD-1 or PD-L1 inhibitors are rare but potentially life-threatening events. The most common clinical presentations are neutropenia, autoimmune haemolytic anaemia, immune thrombocytopenia, and aplastic anaemia. Investigations into earlier detection and better management are warranted. FUNDING: Gustave Roussy and Gustave Roussy Immunotherapy Program.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Delanoy N, Michot JM, Comont T, et al. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol. 2018. PMID: 30528137. doi:10.1016/S2352-3026(18)30175-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。